News

Zevra Therapeutics Announces MIPLYFFA® And OLPRUVA® Presentations At The Annual Meeting Of The Southeastern Regional Genetics Group (SERGG)
Patients were treated with MIPLYFFA in a 48-month open-label extension (OLE) study following the Phase 2/3, randomized, double-blind, placebo-controlled pivotal trial. The OLE data demonstrate that ...